SCHEMBL3484882

SCHEMBL3484882

O=P(O)(O)On1nccn1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.32
BLM P54132 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485667 0.72
SCHEMBL668855 0.67 FDPS (0.40) FDPS
SCHEMBL3486091 0.66 SRC (0.39) FDPS
SCHEMBL10887892 0.59 FDPS (0.33) FDPSBLMTDP1
SCHEMBL1811051 0.55
SCHEMBL7168800 0.55
SCHEMBL8519706 0.55
Pyrazine SCHEMBL16166716 0.53 FDPS (0.37) FDPSTDP1
Pyrophosphoric Acid SCHEMBL21110677 0.53 FDPS (0.83) FDPSBLMTDP1
Peroxymonophosphate SCHEMBL17203123 0.53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029008-A1 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES FEBIT BIOTECH GMBH (DE) 2010-02-04 US claimed
EP-1828217-A2 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES Febit Biotech GmbH (DE) 2007-09-05 EP claimed
WO-2006063717-A2 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES FEBIT BIOTECH GMBH (DE) 2006-06-22 WO claimed
US-20100029008-A1 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES FEBIT BIOTECH GMBH (DE) 2010-02-04 US disclosed
EP-1828217-A2 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES Febit Biotech GmbH (DE) 2007-09-05 EP disclosed
WO-2006063717-A2 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES FEBIT BIOTECH GMBH (DE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029008-A1 POLYMERASE-INDEPENDENT ANALYSIS OF THE SEQUENCE OF POLYNUCLEOTIDES POLB, POLM, POLN FDPS 1225/4885BLM 352/4885TDP1 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.